Alto Neuroscience Inc
ANRO
Company Profile
Business description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Contact
369 South San Antonio Road
Los AltosCA94022
USAT: +1 650 200-0412
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
88
Stocks News & Analysis
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,543.70 | 34.10 | -0.40% |
| CAC 40 | 7,431.04 | 59.24 | -0.79% |
| DAX 40 | 20,214.79 | 102.31 | -0.50% |
| Dow JONES (US) | 41,938.45 | 696.75 | -1.63% |
| FTSE 100 | 8,248.49 | 71.20 | -0.86% |
| HKSE | 19,064.29 | 176.60 | -0.92% |
| NASDAQ | 19,161.63 | 317.25 | -1.63% |
| Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
| NZX 50 Index | 12,895.98 | 47.76 | -0.37% |
| S&P 500 | 5,827.04 | 91.21 | -1.54% |
| S&P/ASX 200 | 8,294.10 | 35.10 | -0.42% |
| SSE Composite Index | 3,168.52 | 42.87 | -1.33% |